Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 11:04 AM ET
Aurinia Pharmaceuticals Inc (AUPH) Competitors
The companies most similar to Aurinia Pharmaceuticals are Nurix Therapeutics (NRIX), Ultragenyx (RARE) and Arcus Biosciences (RCUS). By market cap, Aurinia Pharmaceuticals ranks 5th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B.
Peer Comparison
AUPH's revenue growth of 13.9% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals (AUPH) | $2.11B | 15.2x | 6.4x | 97.7% | N/A | 13.9% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Arcus Biosciences Inc (RCUS) | $2.51B | N/A | 21.5x | 0.0% | -75.9% | -65.4% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Uniqure NV (QURE) | $1.67B | N/A | 75.8x | 0.0% | -57.9% | 40.4% | 0.00% |
| Innoviva Inc (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Biohaven Ltd. (BHVN) | $2.09B | N/A | N/A | 0.0% | -315.9% | 0.0% | 0.00% |
| Pharvaris BV (PHVS) | $2.36B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Xenon Pharmaceuticals Inc (XENE) | $3.98B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| UroGen Pharma Ltd (URGN) | $1.28B | N/A | 5.7x | -26.3% | -73.7% | 223.9% | 0.00% |
| Septerna, Inc. Common Stock (SEPN) | $2.03B | N/A | 20.3x | -61.3% | N/A | -12.2% | 0.00% |
| Peer median | $1.86B | 5.8x | 6.7x | 0.0% | -57.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Aurinia Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Arcus Biosciences Inc (RCUS) | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. | RCUS competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Uniqure NV (QURE) | uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. | QURE competitors |
| Innoviva Inc (INVA) | Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California. | INVA competitors |
| Biohaven Ltd. (BHVN) | Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders... | BHVN competitors |
| Pharvaris BV (PHVS) | Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. | PHVS competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Xenon Pharmaceuticals Inc (XENE) | Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders... | XENE competitors |
| UroGen Pharma Ltd (URGN) | UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases... | URGN competitors |
| Septerna, Inc. Common Stock (SEPN) | Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. | SEPN competitors |
Frequently Asked Questions About AUPH
Who are Aurinia Pharmaceuticals' main competitors?
The companies most similar to Aurinia Pharmaceuticals include Nurix Therapeutics (NRIX), Ultragenyx (RARE), Arcus Biosciences (RCUS), Nuvation Bio (NUVB) and Uniqure NV (QURE), listed from the closest match.
Who is Aurinia Pharmaceuticals' biggest competitor?
Xenon Pharmaceuticals (XENE) is the largest of the similar companies at $3.98B; Nurix Therapeutics (NRIX) is the closest match by business profile, size, sector and industry.
How does AUPH stock compare with its competitors?
AUPH's P/E is 15.2x against a peer median of 5.8x; its P/S is 6.4x against a peer median of 6.7x; its net margin is 97.7% against a peer median of 0.0%.
Which of Aurinia Pharmaceuticals' competitors pays a higher dividend?
Aurinia Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Aurinia Pharmaceuticals bigger than its competitors?
No. Aurinia Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.
AUPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors